Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Salicylate SCHEMBL29784435 | 0.93 | TSHR (0.61) | NPC1SLC6A3HSP90AA1MAPTHTT | |
| SCHEMBL8727421 | 0.85 | SLC6A3 (0.53) | SLC6A3HSP90AA1MAPTHTTNPSR1 | |
| SCHEMBL21434742 | 0.85 | NPC1 (0.44) | NPC1SLC6A3MAPTHTTALDH1A1 | |
| SCHEMBL6948700 | 0.84 | ALDH1A1 (0.52) | SLC6A3HSP90AA1MAPTHTTNPSR1 | |
| SCHEMBL11637190 | 0.83 | LMNA (0.60) | NPC1MAPTHTTALDH1A1L3MBTL1 | |
| SCHEMBL18026668 | 0.83 | HCRTR1 (0.49) | NPC1MAPTMEN1GAAKMT2A | |
| SCHEMBL7349998 | 0.82 | MAOB (0.57) | NPC1SLC6A3HTTNPSR1ALDH1A1 | |
| SCHEMBL5763096 | 0.82 | FFAR4 (0.55) | NPC1SLC6A3ALDH1A1MEN1KMT2A | |
| SCHEMBL15273702 | 0.82 | MAOA (0.45) | NPC1SLC6A3HSP90AA1MAPTHTT | |
| SCHEMBL26040512 | 0.82 | PLK1 (0.46) | NPC1ALDH1A1LMNACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240109899-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (CN) | 2023-02-02 | — | — | US | disclosed |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (CN) | 2023-02-02 | — | — | US | disclosed |
| WO-2022169921-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-11 | — | — | WO | disclosed |
| US-11207325-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-11207325-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| WO-2016103155-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-20100113747-A1 | Coupling of Antibody Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2010-05-06 | — | — | US | disclosed |
| US-20100113747-A1 | Coupling of Antibody Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2010-05-06 | — | — | US | disclosed |
| US-20100113747-A1 | Coupling of Antibody Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2010-05-06 | — | — | US | disclosed |
| EP-2115001-A1 | COUPLING OF ANTIBODY POLYPEPTIDES AT THE C-TERMINUS | Novo Nordisk A/S (DK) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008107260-A1 | COUPLING OF ANTIBODY POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK A/S (DK) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107260-A1 | COUPLING OF ANTIBODY POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK A/S (DK) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | NPC1 2908/4885SLC6A3 3401/4885HSP90AA1 3660/4885 |
| US-11207325-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | NPC1 2908/4885SLC6A3 3401/4885HSP90AA1 3660/4885 |
| US-20100113747-A1 | Coupling of Antibody Polypeptides at the C-Terminus | FCGRT, FCGR3B, FCGR2A | NPC1 4413/4885SLC6A3 4719/4885HSP90AA1 3047/4885 |
| US-20240109899-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | STING1, MAVS, IRF3 | NPC1 692/4885SLC6A3 4629/4885HSP90AA1 1115/4885 |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | NPC1 2908/4885SLC6A3 3401/4885HSP90AA1 3660/4885 |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | NPC1 2908/4885SLC6A3 3401/4885HSP90AA1 3660/4885 |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | NPC1 2908/4885SLC6A3 3401/4885HSP90AA1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.